首站-论文投稿智能助手
典型文献
Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells
文献摘要:
Ovarian cancer is one of the most common gynecologic malignancies in women and has a poor prognosis.Taxanes are a class of standard first-line chemotherapeutic agents for the treatment of ovarian cancer.However,tumor-intrinsic and acquired resistance to taxanes poses major challenges to improving clinical outcomes.Hence,there is an urgent clinical need to understand the mechanisms of resistance in order to discover potential biomarkers and therapeutic strategies to increase taxane sensitivity in ovarian cancer.Here,we report the identification of an association between the TP53 status and taxane sensitivity in ovarian cancer cells through complementary experimental and informatics approaches.We found that TP53 inactivation is associated with taxane resistance in ovarian cancer cells,supported by the evidence from(i)drug sensitivity profiling with bioinformatic analysis of large-scale cancer therapeutic response and genomic datasets and(ii)gene signature identification based on experimental isogenic cell line models.Further,our studies revealed TP53-dependent gene expression patterns,such as overexpression of ACSM3,as potential predictive biomarkers of taxane resistance in ovarian cancer.The TP53-dependent hyperactivation of the WNT/β-catenin pathway discovered herein revealed a potential vulnerability to exploit in developing combination therapeutic strategies.Identification of this genotype-phenotype relationship between the TP53 status and taxane sensitivity sheds light on TP53-directed patient stratification and therapeutic discoveries for ovarian cancer treatment.
文献关键词:
作者姓名:
Changfa Shu;Xi Zheng;Alafate Wuhafu;Danielle Cicka;Sean Doyle;Qiankun Niu;Dacheng Fan;Kun Qian;Andrey A.Ivanov;Yuhong Du;Xiulei Mo;Haian Fu
作者机构:
Department of Pharmacology and Chemical Biology,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Gynecology and Obstetrics,The Third Xiangya Hospital of Central South University,Changsha 410013,China;Cancer Institute,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310052,China;The First Affiliated Hospital,Medical School of Xi'an Jiaotong University,Xi'an 710061,China;Emory Chemical Biology Discovery Center,Emory University School of Medicine,Atlanta,GA 30322,USA;Department of Hematology and Medical Oncology and Winship Cancer Institute,Emory University,Atlanta,GA 30322,USA
引用格式:
[1]Changfa Shu;Xi Zheng;Alafate Wuhafu;Danielle Cicka;Sean Doyle;Qiankun Niu;Dacheng Fan;Kun Qian;Andrey A.Ivanov;Yuhong Du;Xiulei Mo;Haian Fu-.Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells)[J].中国药理学报(英文版),2022(09):2419-2428
A类:
Taxanes,taxanes,hyperactivation
B类:
Acquisition,resistance,by,p53,inactivation,ovarian,cancer,cells,Ovarian,one,most,common,gynecologic,malignancies,women,has,poor,prognosis,are,class,standard,first,line,chemotherapeutic,agents,treatment,However,tumor,intrinsic,acquired,poses,major,challenges,improving,clinical,outcomes,Hence,there,urgent,need,understand,mechanisms,order,potential,biomarkers,strategies,increase,sensitivity,Here,report,identification,association,between,TP53,status,through,complementary,experimental,informatics,approaches,We,found,that,associated,supported,evidence,from,drug,profiling,bioinformatic,analysis,large,scale,response,genomic,datasets,ii,gene,signature,isogenic,models,Further,our,studies,revealed,dependent,patterns,such,overexpression,ACSM3,predictive,WNT,catenin,pathway,discovered,herein,vulnerability,exploit,developing,combination,Identification,this,genotype,phenotype,relationship,sheds,light,directed,patient,stratification,discoveries
AB值:
0.548525
相似文献
N6?methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance
Xian Lin;Feng Wang;Jian Chen;Jing Liu;Yi?Bin Lin;Li Li;Chuan?Ben Chen;Qin Xu-Departments of Gynecology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Department of Radiation Oncology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Shenzhen Key Laboratory of Immunity and Inflammatory Diseases,Peking University Shenzhen Hospital,Shenzhen Peking University?the Hong Kong University of Science and Technology Medical Center,Shenzhen 518036,Guangdong,China;Outpatient Department,Fujian Hospital of People's Armed Police,Fujian Medical University,Fuzhou 350014,China
Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells
Yu Yu;Minzhen Tao;Libin Xu;Lei Cao;Baoyu Le;Na An;Jilin Dong;Yajie Xu;Baoxing Yang;Wei Li;Bing Liu;Qiong Wu;Yinying Lu;Zhen Xie;Xiaohua Lian-Department of Cell Biology,Basic Medical College,Army Medical University(Third Military Medical University),Chongqing 400038,China;MOE Key Laboratory of Bioinformatics and Bioinformatics Division,Center for Synthetic and System Biology,Department of Automation,Beijing National Research Center for Information Science and Technology,Tsinghua University,Beijing 100084,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Syngentech Co.,Ltd,Beijing 102206,China;School of Life Sciences,Tsinghua University,Beijing 100084,China;The Comprehensive Liver Cancer Center,The 5th Medical Center of PLA General Hospital,Beijing 100039,China
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
Duo Zuo;Yongzi Chen;Xinwei Zhang;Zhuozhi Wang;Wenna Jiang;Fan Tang;Runfen Cheng;Yi Sun;Lu Sun;Li Ren;Rui Liu-Department of Clinical Laboratory;Department of Tumor Cell Biology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Biomedical Engineering,Tianjin Medical University,Tianjin 300070,China;Department of Pathology,Tianjin Huanhu Hospital,Tianjin 300350,China;Department of Pathology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Pharmacy,Tianjin Medical University,Tianjin 300070,China;Department of Gastrointestinal Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer
Qiong Wang;Zean Li;Jin Yang;Shirong Peng;Qianghua Zhou;Kai Yao;Wenli Cai;Zhongqiu Xie;Fujun Qin;Hui Li;Xu Chen;Kaiwen Li;Hai Huang-Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Pathology,School of Medicine,University of Virginia,Charlottesville,VA 22908,USA;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Radiation Oncology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China;Department of Urology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Department of Radiology,Massachusetts General Hospital,Harvard Medical School,Boston,MA 02114,USA;Department of Urology,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Preclinical studies of the triazol0[1,5-a]pyrimidine derivative WS-716 as a highly potent,specific and orally active P-glycoprotein(P-gp)inhibitor
Sai-Qi Wang;Qiu-Xu Teng;Shuai Wang;Zi-Ning Lei;Hui-Hui Hu;Hui-Fang Lv;Bei-Bei Chen;Jian-Zheng Wang;Xiao-Jing Shi;Wei-Feng Xu;Hong-Min Liu;Xiao-Bing Chen;Zhe-Sheng Chen;Bin Yu-Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Henan Cancer Institute,Zhengzhou 450008,China;State Key Laboratory of Esophageal Cancer Prevention&Treatment,Zhengzhou University,Zhengzhou 450052,China;College of Pharmacy and Health Sciences,St.John,s University,Queens,NY 11439,USA;School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China;Laboratory Animal Center,Academy of Medical Science,Zhengzhou University,Zhengzhou 450052,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。